Coulter Partners: Views from Leadership
Coulter Partners recently talked about the importance of diversity, equity and inclusion in Life Sciences with Annalisa Jenkins, MBBS, FRCP. Dr. Jenkins serves as Chair and Independent Director on the boards of several Biopharma organizations and was previously President and CEO of Dimension Therapeutics.
“To be innovative, competitive and disruptive, we need to be inclusive.”
Annalisa Jenkins, MBBS, FRCP, chairs or sits on the boards of over a dozen Life Sciences organizations and was most recently appointed Non-executive Director of Genomics England. She previously served as President and CEO of Dimension Therapeutics and has held multiple leadership positions, including Executive Vice President, Head of Global Research and Development for Merck Serono, where she led global medical affairs and quality and was a member the Pharmaceutical Executive Committee.
This interview is the first in Coulter Partners' series with Industry leaders on D, E & I. Some of the following questions are answered:
- What changed to make women more confident in speaking out for inclusion?
- How do you differentiate between Diversity and Inclusion in today’s world?
- Specific to Life Sciences, why is D, E & I so important?
- Over your career, what key developments have you seen that have promoted more diversity, equity and inclusion in the workplace?